danoprevir

Danoprevir is an orally available, small molecule, macrocyclic peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. It was originally discovered by InterMune and Array BioPharma, with development rights later acquired by Roche and co-developed in China with Ascletis. Danoprevir is approved in China for the treatment of chronic HCV genotype 1b infection without cirrhosis. The drug acts by binding noncovalently to the catalytic site of the HCV NS3/4A protease, thereby blocking cleavage of viral polyproteins required for viral replication and maturation. Danoprevir has demonstrated potent activity against multiple HCV genotypes and key resistance mutants. It is typically administered orally in combination with ritonavir (a CYP3A inhibitor), peginterferon alfa-2a, and ribavirin to enhance its antiviral effect[1][2][3][6]. There has also been investigation into its potential use against SARS-CoV-2 due to similar mechanisms involving viral proteases[2][4].

Brand names

Ganovo

Other names

danoprevir